Research programme: polyclonal antibodies - SAB Biotherapeutics

Drug Profile

Research programme: polyclonal antibodies - SAB Biotherapeutics

Latest Information Update: 03 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SAB Biotherapeutics
  • Class Antibacterials; Antineoplastics; Antivirals; Polyclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alphavirus infections; Cancer; Clostridium-difficile-infections; Dengue; Ebola virus infections; Hantavirus infections; Influenza virus infections; Mycoplasma infections; Viral haemorrhagic fevers; Zika virus infection

Most Recent Events

  • 26 Apr 2017 Preclinical trials in Clostridium difficile infections in USA (unspecified route)
  • 26 Apr 2017 Preclinical trials in Zika virus infection in USA (unspecified route)
  • 07 Sep 2016 SAB Biotherapeutics receives SBIR grant from the National Institutes of Health for the antibody therapeutic targeting influenza viruses
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top